BeOne Medicines (ONC) Equity Income (2020 - 2023)

BeOne Medicines (ONC) has 4 years of Equity Income data on file, last reported at -$3.9 million in Q4 2023.

• Quarterly Equity Income rose 29.29% year-over-year to -$3.9 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was -$6.3 million (up 79.88% YoY) and the FY2023 annual result came in at -$16.2 million, up 26.25% from the prior year.
• Equity Income retreated to -$3.9 million in Q4 2023 per ONC's latest filing, from -$2.7 million in the prior quarter.
• Across five years, Equity Income topped out at $23.8 million in Q3 2021 and bottomed at -$17.0 million in Q1 2022.
• The 4-year median for Equity Income is -$2.5 million (2021), against an average of -$1.0 million.
• Peak annual rise in Equity Income reached 16718.18% in 2021, while the deepest fall reached 614.79% in 2021.
• Tracing ONC's Equity Income over 4 years: stood at $1.9 million in 2020, then tumbled by 614.79% to -$9.5 million in 2021, then jumped by 41.44% to -$5.6 million in 2022, then increased by 29.29% to -$3.9 million in 2023.
• Per Business Quant, the three latest ONC Equity Income figures stand at -$3.9 million (Q4 2023), -$2.7 million (Q3 2023), and $470000.0 (Q2 2023).

Peer Comparison